Security
Grace Therapeutics, Inc. Common Stock · GRCE
GRCENASDAQCommon stockCurrentCIK 1444192Updated Nov 14, 2026
Name history
Acasti Pharma Inc. · through Oct 25, 2024
GRCE price & chart
Loading TradingView…
NASDAQ:GRCE on TradingView ↗About the company
Grace Therapeutics, Inc. (Grace Therapeutics or the Company) is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Grace Therapeutics’ novel drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery. Grace Therapeutics’ lead clinical asset, GTx-104, is an IV infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull. GTx-104 has been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States if certain conditions are met at NDA approval, and additional intellectual property protection with 52 granted and pending patents.
In the news
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc. - GRCE ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc. - GRCE ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc. - GRCE ↗
Seeking Alpha
Grace Therapeutics GAAP EPS of -$0.11 beats by $0.04 ↗
Grace Therapeutics prices $10M private placement ↗
Grace Therapeutics: Assessing The Path Forward For GTx-104 ↗
SEC disclosures
Grace Therapeutics, Inc. files 8-K: Material Event ↗
Recent filings
Financials
FY 2026 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2026 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2027 | Q1 2026 | Q1 2025 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 68,488,000Source | 61,224,000Source | 76,185,000Source | 66,576,000Source | 65,349,000Source | 50,073,000Source | 69,805,000Source | — | 66,654,000Source | 71,993,000Source | 73,300,000Source | 79,123,000Source |
| Property, Plant and Equipment, NetUSD | — | — | — | — | — | — | — | — | 8,000Source | 15,000Source | 24,000Source | 12,198,000Source |
| GoodwillUSD | 8,138,000Source | 8,138,000Source | 8,138,000Source | 8,138,000Source | 8,138,000Source | 8,138,000Source | 8,138,000Source | — | 8,138,000Source | 8,138,000Source | 8,138,000Source | 8,138,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 41,128,000Source | 41,128,000Source | 41,128,000Source | 41,128,000Source | 41,128,000Source | 27,595,000Source | 41,128,000Source | — | 41,128,000Source | 41,128,000Source | 41,128,000Source | 41,128,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 18,672,000Source | 11,055,000Source | 18,545,000Source | 16,862,000Source | 15,155,000Source | 13,756,000Source | 20,005,000Source | — | 16,977,000Source | 22,133,000Source | 23,005,000Source | 27,875,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | 959,000Source | — | — | — | — | — | — | — | 722,000Source | 802,000Source |
| Assets, CurrentUSD | 19,211,000Source | 11,939,000Source | 26,884,000Source | 17,298,000Source | 16,062,000Source | 14,333,000Source | 20,525,000Source | — | 17,380,000Source | 22,712,000Source | 24,010,000Source | 29,290,000Source |
| Operating Lease, Right-of-Use AssetUSD | — | — | 23,000Source | — | — | — | — | — | — | — | 0Source | 463,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 3,596,000Source | 9,085,000Source | 11,505,000Source | 3,758,000Source | 9,215,000Source | 1,862,000Source | 6,255,000Source | — | 2,758,000Source | 5,383,000Source | 11,557,000Source | 11,168,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | — | 0Source | — | 0Source | 0Source | — | 0Source | 0Source | — | — |
| Common Stock, Value, IssuedUSD | 1,000Source | 1,000Source | — | 1,000Source | — | 1,000Source | 1,000Source | — | 1,000Source | 1,000Source | — | 258,294,000Source |
| Additional Paid in CapitalUSD | 298,231,000Source | 279,499,000Source | 17,633,000Source | 293,842,000Source | 18,302,000Source | 298,518,000Source | 293,636,000Source | — | 298,413,000Source | 293,334,000Source | 17,862,000Source | 13,965,000Source |
| Retained Earnings (Accumulated Deficit)USD | -227,302,000Source | -221,323,000Source | -207,953,000Source | -224,987,000Source | -217,168,000Source | -244,270,000Source | -224,049,000Source | — | -228,480,000Source | -220,687,000Source | -211,119,000Source | -198,266,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -6,038,000Source | -6,038,000Source | -6,038,000Source | -6,038,000Source | -6,038,000Source | -6,038,000Source | -6,038,000Source | — | -6,038,000Source | -6,038,000Source | -6,038,000Source | -6,038,000Source |
| Stockholders' Equity Attributable to ParentUSD | 64,892,000Source | 52,139,000Source | 64,680,000Source | 62,818,000Source | 56,134,000Source | 48,211,000Source | 63,550,000Source | 59,364,000Source | 63,896,000Source | 66,610,000Source | 61,743,000Source | 67,955,000Source |
| Liabilities and EquityUSD | 68,488,000Source | 61,224,000Source | 76,185,000Source | 66,576,000Source | 65,349,000Source | 50,073,000Source | 69,805,000Source | — | 66,654,000Source | 71,993,000Source | 73,300,000Source | 79,123,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 1,284,000Source | 1,971,000Source | 1,770,000Source | 1,245,000Source | 2,674,000Source | 1,250,000Source | 2,315,000Source | — | 2,146,000Source | 1,930,000Source | 1,684,000Source | 3,411,000Source |
| Operating Lease, Liability, CurrentUSD | — | — | 24,000Source | — | — | — | — | — | — | — | 0Source | 75,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | 0Source | — | — | — | — | — | — | — | 0Source | 410,000Source |
| Deferred Income Tax Liabilities, NetUSD | 2,312,000Source | 3,333,000Source | 6,403,000Source | 2,312,000Source | 3,938,000Source | 612,000Source | 2,312,000Source | — | 612,000Source | 2,312,000Source | 5,514,000Source | 7,347,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | — | — | 532,000Source | — | — | — | — | — | — | — | 176,000Source | 946,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 612,000Source | — | — | — |
| Short-term InvestmentsUSD | — | — | 6,569,000Source | — | 15,000Source | — | — | — | — | — | 0Source | 15,000Source |
cash flow · annual statements
| Line item | Q4 2026 | Q4 2025 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2027 | Q1 2026 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 105,000Source | 302,000Source | 798,000Source | 730,000Source | 913,000Source | 1,811,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | 0Source | -1,700,000Source | -3,202,000Source | -1,834,000Source | -9,542,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -3,221,000Source | -1,801,000Source | -8,869,000Source | -14,904,000Source | -12,333,000Source | -15,913,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 104,000Source | 13,153,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 0Source | -327,000Source | 3,713,000Source | 14,032,000Source | 7,359,000Source | 304,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -3,221,000Source | -2,128,000Source | -5,156,000Source | -872,000Source | -4,870,000Source | -2,464,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 18,672,000Source | 11,055,000Source | 16,862,000Source | 15,155,000Source | 13,756,000Source | 20,005,000Source | 16,977,000Source | 22,133,000Source | — | — |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 12,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| DepreciationUSD | — | — | — | — | — | — | 2,000Source | 2,000Source | 7,000Source | 7,000Source | 11,000Source | 124,000Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | — | — | 4,000Source | -16,000Source | -8,000Source | 13,000Source | -14,000Source | 10,000Source | -1,000Source | -17,000Source | -16,000Source | -72,000Source |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | — | — | — | — | — | — | — | — | — | — | 0Source | -5,000Source |
| Gain (Loss) on Disposition of Intangible AssetsUSD | — | — | — | — | — | — | — | — | — | — | -39,000Source | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | — | 0Source | 59,000Source | — |
| General and Administrative ExpenseUSD | — | — | 1,987,000Source | 1,510,000Source | 1,961,000Source | 1,855,000Source | 1,687,000Source | 2,135,000Source | 8,672,000Source | 7,168,000Source | 6,432,000Source | 7,614,000Source |
| GoodwillUSD | — | — | 8,138,000Source | 8,138,000Source | 8,138,000Source | 8,138,000Source | 8,138,000Source | 8,138,000Source | 8,138,000Source | 8,138,000Source | 8,138,000Source | 8,138,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | 0Source | — | 0Source | 0Source | — | — |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 28,682,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | -605,000Source | 0Source | -852,000Source | 0Source | 0Source | -1,700,000Source | -3,199,000Source | -1,832,000Source | -9,542,000Source |
| Investment Income, InterestUSD | — | — | 170,000Source | 138,000Source | 172,000Source | 172,000Source | 141,000Source | 205,000Source | 685,000Source | 711,000Source | 911,000Source | 246,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -2,315,000Source | -4,155,000Source | -938,000Source | -3,432,000Source | -15,790,000Source | -3,362,000Source | -7,793,000Source | -9,568,000Source | -12,853,000Source | -42,429,000Source |
| Nonoperating Income (Expense)USD | — | — | 134,000Source | -1,056,000Source | 1,591,000Source | 547,000Source | 127,000Source | -272,000Source | 1,584,000Source | 3,912,000Source | -1,833,000Source | 184,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 93,000Source | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 304,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | — | 0Source | — | — |
| Impairment of Intangible Assets (Excluding Goodwill) | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2026 | Q4 2025 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2027 | Q1 2026 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -2,449,000Source | -3,704,000Source | -2,529,000Source | -4,831,000Source | -15,917,000Source | -3,090,000Source | -11,077,000Source | -16,679,000Source | -12,852,000Source | -52,155,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -2,315,000Source | -4,760,000Source | -938,000Source | -4,284,000Source | -15,790,000Source | -3,362,000Source | -9,493,000Source | -12,767,000Source | -14,685,000Source | -51,971,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | -605,000Source | 0Source | -852,000Source | 0Source | 0Source | -1,700,000Source | -3,199,000Source | -1,832,000Source | -9,542,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -2,315,000Source | -4,155,000Source | -938,000Source | -3,432,000Source | -15,790,000Source | -3,362,000Source | -7,793,000Source | -9,568,000Source | -12,853,000Source | -42,429,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.14Source | -0.36Source | -0.06Source | -0.3Source | -0.91Source | -0.21Source | -0.47Source | -0.79Source | -1.35Source | -0.95Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.14Source | -0.36Source | -0.06Source | -0.3Source | -0.91Source | -0.21Source | -0.47Source | -0.79Source | -1.35Source | -0.95Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 16,933,620Source | 11,506,234Source | 15,924,522Source | 11,506,234Source | 17,269,986Source | 15,924,522Source | 16,510,632Source | 12,087,270Source | 9,529,123Source | 44,612,831Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 16,933,620Source | 11,506,234Source | 15,924,522Source | 11,506,234Source | 17,269,986Source | 15,924,522Source | 16,510,632Source | 12,087,270Source | 9,529,123Source | 44,612,831Source |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 3,000Source | 2,000Source | 0Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | — | — | 4,000Source | -16,000Source | -8,000Source | 13,000Source | -14,000Source | 10,000Source | -1,000Source | -17,000Source | -16,000Source | -72,000Source |
| General and Administrative ExpenseUSD | — | — | 1,987,000Source | 1,510,000Source | 1,961,000Source | 1,855,000Source | 1,687,000Source | 2,135,000Source | 8,672,000Source | 7,168,000Source | 6,432,000Source | 7,614,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | 0Source | — | 0Source | 0Source | — | — |
| Investment Income, InterestUSD | — | — | 170,000Source | 138,000Source | 172,000Source | 172,000Source | 141,000Source | 205,000Source | 685,000Source | 711,000Source | 911,000Source | 246,000Source |
| Nonoperating Income (Expense)USD | — | — | 134,000Source | -1,056,000Source | 1,591,000Source | 547,000Source | 127,000Source | -272,000Source | 1,584,000Source | 3,912,000Source | -1,833,000Source | 184,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 93,000Source | — |
| Other IncomeUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Research and Development ExpenseUSD | — | — | 462,000Source | 2,194,000Source | 568,000Source | 2,976,000Source | 697,000Source | 955,000Source | 2,405,000Source | 9,511,000Source | 4,683,000Source | 9,972,000Source |
| Restructuring and Related Cost, Incurred CostUSD | — | — | — | 0Source | — | 0Source | — | — | — | 0Source | 1,485,000Source | — |
| Selling and Marketing ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 252,000Source | 661,000Source |
Offerings
Registration 333-298522
Filing attachments
ef20085030_ex99-1.htm · 8-K · 2026-11-12
Exhibit 99.1 Grace Therapeutics Announces Second Quarter 2027 Financial Results, Provides Business Update Princeton, N.J., November 12, 2026 (GLOBE NEWSWIRE) - Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage biopharma company advancing GTx-104, a novel, injectable formulation of nimodipine that has completed a Phase 3 clinical trial and is being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced the …
Read attachment ↗ny20080485x1_ex107.htm · S-3 · 2026-08-24
Exhibit 107 CALCULATION OF FILING FEE TABLE S-3 (Form Type) Grace Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registrat…
Read attachment ↗ef20079525_ex99-1.htm · 8-K · 2026-08-13
EX-99.1 2 ef20079525_ex99-1.htm EXHIBIT 99.1 Exhibit 99. 1 Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update Princeton, NJ, August 13, 2026 (GLOBE NEWSWIRE) - Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today ann…
Read attachment ↗ex99-1.htm · SCHEDULE 13G · 2026-08-07
Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of August 7, 2026, is by and among Opaleye Management Inc., Opaleye, L.P. and James Silverman (collectively, the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13D and/or 13G with respect to shares of Common Stock of Grace Therapeutics, Inc. beneficially owned by them from time to time. Pursuant to and in accordance with Rule 13d-1…
Read attachment ↗ef20079559_ex99-1.htm · 8-K · 2026-08-06
EX-99.1 4 ef20079559_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Grace Therapeutics Announces $10 Million Private Placement Expected gross proceeds anticipated to extend the Company’s cash runway to the end of calendar 2028 PRINCETON, N.J., August 4, 2026 - Grace Therapeutics, Inc. (Nasdaq: GRCE) (“Grace Therapeutics” or “the Company”), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address signi…
Read attachment ↗ef20078866_ex99-1.htm · 8-K · 2026-07-28
EX-99.1 2 ef20078866_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration FDA Did Not Identify Any Clinical Safety or Efficacy Deficiencies and Did Not Request Additional Clinical Data Company Advancing a Dual-Source Manufacturing Strategy, Adding a U.S.-Based Site, Toward NDA Resubmission Princeton, NJ, July 28, 2026 (GLOBE NEWSWIRE) - Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the…
Read attachment ↗